These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 7847423)

  • 1. Pharmacoeconomic analysis in formulary decisions: an international perspective.
    Johnson JA; Bootman JL
    Am J Hosp Pharm; 1994 Oct; 51(20):2593-8. PubMed ID: 7847423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic series: Part 3. Applying pharmacoeconomic and quality-of-life measures to the formulary management process.
    Skaer TL
    Hosp Formul; 1993 Jun; 28(6):577-84. PubMed ID: 10126586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating quality of life data into managed care formulary decisions: a case study with salmeterol.
    Bukstein DA
    Am J Manag Care; 1997 Nov; 3(11):1701-6. PubMed ID: 10178468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to use structured decision making in developing therapeutic, cost-effective formulary systems.
    Crane VS
    Hosp Formul; 1993 Oct; 28(10):859-62, 865-7. PubMed ID: 10129135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulary decision making: identifying factors that influence P&T committee drug evaluations.
    Segal R; Pathak DS
    Hosp Formul; 1988 Feb; 23(2):174-8. PubMed ID: 10286022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P & T Committee formulary requests: criteria for admission.
    Weintraub M; Guttmacher L
    Hosp Formul; 1984 Oct; 19(10):975-7, 980. PubMed ID: 10268315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formularies: the role of pharmacy-and-therapeutics (P&T) committees.
    Summers KH; Szeinbach SL
    Clin Ther; 1993; 15(2):433-41; discussion 432. PubMed ID: 8519049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of pharmacoeconomic guidelines for formulary approval: the Australian experience.
    Langley PC
    Clin Ther; 1993; 15(6):1154-76; discussion 1120. PubMed ID: 8111812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons from formulary decisionmaking.
    Langley PC
    Qual Lett Healthc Lead; 1997 Sep; 9(8):10-3. PubMed ID: 10170205
    [No Abstract]   [Full Text] [Related]  

  • 10. The case for a value-based formulary: striving for total lowest net cost.
    Weart W; Bauman GR
    Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to develop a proactive formulary system.
    Crane VS; Gonzalez ER; Hull BL
    Hosp Formul; 1994 Oct; 29(10):700-2, 704-8, 710. PubMed ID: 10137847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomics and the formulary decision-making process.
    Bakst A
    Hosp Formul; 1995 Jan; 30(1):42-50. PubMed ID: 10172201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Praxis makes perfect?
    Fins JJ
    Hastings Cent Rep; 1993; 23(5):16-9. PubMed ID: 7710462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weighing the evidence: trends in managed care formulary decision making.
    de Lissovoy G
    J Clin Psychiatry; 2003; 64 Suppl 17():29-32. PubMed ID: 14680425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomics and formulary decision making.
    Sanchez LA
    Pharmacoeconomics; 1996; 9 Suppl 1():16-25. PubMed ID: 10160112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of pharmacoeconomics to formulary decision making in managed care organizations.
    Suh DC; Okpara IR; Agnese WB; Toscani M
    Am J Manag Care; 2002 Feb; 8(2):161-9. PubMed ID: 11858228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P & T Committee interview: strategies to ensure an effective formulary system.
    Riff L; Hutchinson R
    Hosp Formul; 1988 Nov; 23(11):901-4, 907-8. PubMed ID: 10290754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A call for fairness in formulary decisions.
    Levinson W; Laupacis A
    Arch Intern Med; 2006 Jan; 166(1):16-8. PubMed ID: 16401806
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacy and Therapeutics committee. Cost-containment considerations.
    Hochla PK; Tuason VB
    Arch Intern Med; 1992 Sep; 152(9):1773-5. PubMed ID: 1520043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to develop critical paths and prepare for other formulary management changes.
    McCaffrey S; Nightingale CH
    Hosp Formul; 1994 Sep; 29(9):628-32, 635. PubMed ID: 10137059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.